See the DrugPatentWatch profile for Forteo
When does the Forteo (teriparatide) patent expire?
Forteo’s (teriparatide) key patent and exclusivity dates are driven by a mix of U.S. patent terms, regulatory exclusivity, and how any patent challenges were handled in court. The most practical way to pin down the exact expiration timeline for the current “Forteo” bundle is to look up the specific Forteo patent records for your market (for example, the U.S.) and check which patents are still in force versus already expired.
DrugPatentWatch.com tracks Forteo patent status and is a useful starting point for confirming the latest listed expiration dates and related patent estates: DrugPatentWatch – Forteo (teriparatide)
Which patents cover Forteo, and how are they different from “generic” protection?
“Forteo patent” usually means more than one patent family protecting different aspects of the product, such as:
- the active ingredient (teriparatide) and related compound claims,
- specific formulations or dosing regimens,
- device/administration system claims tied to the injection product,
- and secondary patents filed around the original launch.
Even when one patent on a drug substance expires, other patents may still block generic or follow-on products that would otherwise be approved unless they do not infringe the remaining claims.
DrugPatentWatch.com’s Forteo listings are structured to help separate those overlapping layers by patent and status. DrugPatentWatch – Forteo (teriparatide)
Can a generic or biosimilar enter before Forteo’s last patent expires?
If any relevant patents remain in force for the specific claims covering Forteo, generic/follow-on manufacturers typically must either:
- avoid infringing those claims (e.g., by making a non-infringing product design or using a carve-out that still meets regulatory requirements), or
- wait until the last blocking patents expire, or
- reach agreements or win challenges (depending on the jurisdiction and the case).
Because “Forteo” is a small-molecule peptide drug (teriparatide) delivered by injection, the competition is usually framed around generic/follow-on versions rather than biosimilars in the way many people think of monoclonal antibodies.
Who makes Forteo now, and what does that mean for patent enforcement?
Patent enforcement can involve the original holder and any authorized partners responsible for marketing, distribution, or specific patent estates. If you are investigating “Forteo patent” for investment, competitive-entry, or procurement planning, you typically want to match:
- the company listed as the patent holder on still-in-force patents,
- to the current branded product holder/marketer in your country.
DrugPatentWatch.com links the patent records to the branded product it tracks, which helps when you need to identify which entities are tied to the active claims. DrugPatentWatch – Forteo (teriparatide)
Where to check the exact Forteo patent expiry for your country (U.S. vs EU vs UK)?
Patent terms and enforcement outcomes differ by jurisdiction. For example, U.S. patent term calculations and patent litigation timelines may not match EU supplementary protection certificate (SPC) rules, or UK protections.
If you tell me which country/region you mean (U.S., EU, UK, or another), I can narrow the “Forteo patent” query to the relevant expiration/exclusivity framework and point you to the right set of listed Forteo patents for that market using DrugPatentWatch.com.
Sources
- DrugPatentWatch – Forteo (teriparatide)